By Elaine Rigoli
Tampa, Fla., June 5 - Hercules Technology Growth Capital, Inc. provided $10 million of debt financing to TransOral Pharmaceuticals, Inc.
TransOral is developing a rapidly acting version of sumatriptan, seeking to provide "injection-like" migraine relief from a chewable tablet, according to a news release.
TransOral's Intermezzo is in phase 2 development for middle-of-the-night insomnia.
Hercules, a specialty finance company providing debt and equity growth capital to technology-related companies at all stages of development, has headquarters in Palo Alto, Calif.
TransOral is a specialty pharmaceutical company located in Pt. Richmond, Calif.
| Issuer: | TransOral Pharmaceuticals, Inc.
|
| Issue: | Debt financing
|
| Amount: | $10 million
|
| Investors: | Hercules Technology Growth Capital, Inc.
|
| Announcement date: | June 5
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
